🎉 M&A multiples are live!
Check it out!

4D Molecular Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for 4D Molecular Therapeutics and other public comps.

See 4D Molecular Therapeutics Valuation Multiples

4D Molecular Therapeutics Overview

About 4D Molecular Therapeutics

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.


Founded

2015

HQ

United States of America
Employees

147

Financials

LTM Revenue $1.6M

LTM EBITDA -$180M

EV

-$201M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

4D Molecular Therapeutics Financials

4D Molecular Therapeutics has a last 12-month revenue of $1.6M and a last 12-month EBITDA of -$180M.

In the most recent fiscal year, 4D Molecular Therapeutics achieved revenue of $20.7M and an EBITDA of -$107M.

4D Molecular Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See 4D Molecular Therapeutics valuation multiples based on analyst estimates

4D Molecular Therapeutics P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $3.1M $20.7M $1.4M $1.6M XXX
Gross Profit n/a n/a n/a XXX XXX
Gross Margin NaN% NaN% NaN% XXX XXX
EBITDA -$106M -$107M -$175M -$180M XXX
EBITDA Margin -3393% -517% -12559% -10934% XXX
Net Profit -$71.3M -$107M -$101M XXX XXX
Net Margin -2279% -519% -7229% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

4D Molecular Therapeutics Stock Performance

As of February 7, 2025, 4D Molecular Therapeutics's stock price is $6.

4D Molecular Therapeutics has current market cap of $276M, and EV of -$201M.

See 4D Molecular Therapeutics trading valuation data

4D Molecular Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$201M $276M XXX XXX XXX XXX $-2.97

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

4D Molecular Therapeutics Valuation Multiples

As of February 7, 2025, 4D Molecular Therapeutics has market cap of $276M and EV of -$201M.

4D Molecular Therapeutics's trades at -122.1x LTM EV/Revenue multiple, and 1.1x LTM EBITDA.

Analysts estimate 4D Molecular Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for 4D Molecular Therapeutics and 10K+ public comps

4D Molecular Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$201M XXX XXX XXX
EV/Revenue -144.2x XXX XXX XXX
EV/EBITDA 1.1x XXX XXX XXX
P/E -1.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get 4D Molecular Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

4D Molecular Therapeutics Valuation Multiples

4D Molecular Therapeutics's NTM/LTM revenue growth is 133%

4D Molecular Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, 4D Molecular Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate 4D Molecular Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for 4D Molecular Therapeutics and other 10K+ public comps

4D Molecular Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -93% XXX XXX XXX XXX
EBITDA Margin -12559% XXX XXX XXX XXX
EBITDA Growth 64% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -12426% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 176% XXX XXX XXX XXX
R&D Expenses to Revenue 469% XXX XXX XXX XXX
Opex to Revenue 645% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

4D Molecular Therapeutics Public Comps

See valuation multiples for 4D Molecular Therapeutics public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

4D Molecular Therapeutics M&A and Investment Activity

4D Molecular Therapeutics acquired  XXX companies to date.

Last acquisition by 4D Molecular Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . 4D Molecular Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by 4D Molecular Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About 4D Molecular Therapeutics

When was 4D Molecular Therapeutics founded? 4D Molecular Therapeutics was founded in 2015.
Where is 4D Molecular Therapeutics headquartered? 4D Molecular Therapeutics is headquartered in United States of America.
How many employees does 4D Molecular Therapeutics have? As of today, 4D Molecular Therapeutics has 147 employees.
Who is the CEO of 4D Molecular Therapeutics? 4D Molecular Therapeutics's CEO is Mr. David Kirn, M.D..
Is 4D Molecular Therapeutics publicy listed? Yes, 4D Molecular Therapeutics is a public company listed on NAS.
What is the stock symbol of 4D Molecular Therapeutics? 4D Molecular Therapeutics trades under FDMT ticker.
When did 4D Molecular Therapeutics go public? 4D Molecular Therapeutics went public in 2020.
Who are competitors of 4D Molecular Therapeutics? Similar companies to 4D Molecular Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of 4D Molecular Therapeutics? 4D Molecular Therapeutics's current market cap is $276M
What is the current revenue of 4D Molecular Therapeutics? 4D Molecular Therapeutics's last 12-month revenue is $1.6M.
What is the current EBITDA of 4D Molecular Therapeutics? 4D Molecular Therapeutics's last 12-month EBITDA is -$180M.
What is the current EV/Revenue multiple of 4D Molecular Therapeutics? Current revenue multiple of 4D Molecular Therapeutics is -122.1x.
What is the current EV/EBITDA multiple of 4D Molecular Therapeutics? Current EBITDA multiple of 4D Molecular Therapeutics is 1.1x.
What is the current revenue growth of 4D Molecular Therapeutics? 4D Molecular Therapeutics revenue growth between 2023 and 2024 was -93%.
Is 4D Molecular Therapeutics profitable? Yes, 4D Molecular Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.